Prolonged Edoxaban in Patients With Low Body Weight and Cancer-Associated Isolated Distal Deep Vein Thrombosis

Prolonged Edoxaban in Patients With Low Body Weight and Cancer-Associated Isolated Distal Deep Vein Thrombosis

Background: The ONCO DVT study revealed that 12-month edoxaban treatment for cancer-associated isolated distal deep vein thrombosis (IDDVT) was superior to 3-month edoxaban treatment. However, the influence of body weight on efficacy and safety remains unknown. Objectives: We compared 12-month and 3...

Full description

Saved in:
Bibliographic Details
Main Authors: Tomoyuki Nagai, MD, Naohiko Nakanishi, MD, Yugo Yamashita, MD, Takeshi Morimoto, MPH, MD, Nao Muraoka, MD, Michihisa Umetsu, MD, Yuji Nishimoto, MD, Takuma Takada, MD, Yoshito Ogihara, MD, Tatsuya Nishikawa, MD, Nobutaka Ikeda, MD, Kazunori Otsui, MD, Daisuke Sueta, MD, Yukari Tsubata, MD, Masaaki Shoji, MD, Ayumi Shikama, MD, Yutaka Hosoi, MD, Yasuhiro Tanabe, MD, Ryuki Chatani, MD, Kengo Tsukahara, MD, Kitae Kim, MD, Satoshi Ikeda, MD, Takeshi Kimura, MD, Satoaki Matoba, MD
Format: Article
Language:English
Published: Elsevier 2025-08-01
Series:JACC: Advances
Subjects:
cancer-associated thrombosis
edoxaban
isolated distal deep vein thrombosis
low body weight
venous thromboembolism
Online Access:http://www.sciencedirect.com/science/article/pii/S2772963X25003771
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items